PMW usage phase III oncology trials professional medical writer assistance

Professional Medical Writer Assistance in Oncology Clinical Trials

by Ramez Kouzy , Joseph Abi Jaoude , Walker Mainwaring , Timothy A. Lin , Austin B. Miller , Amit Jethanandani , Andres F. Espinoza , Vivek Verma , Clifton D. Fuller , Bruce D. Minsky , Claus Rödel , Cullen M. Taniguchi , Ethan B. Ludmir

Sep 17^th 2020
7 mins
The Oncologist, Volume 25, Issue 11, November 2020, Pages e1812–e1815

Share This Article

Summary

The use of professional medical writers (PMWs) in oncologic phase III randomized controlled trials (RCTs) has been historically low, but recent data on their usage is limited.
This study aimed to quantify the usage of PMWs in cancer-specific phase III RCTs by analyzing trial manuscripts on ClinicalTrials.gov.
Out of 600 trials, 260 (43.3%) involved PMWs in writing the trial manuscript.
Industry-funded trials were significantly more likely to use PMWs compared to nonindustry trials (54.9% vs. 3.0%, p < .001).
PMW usage was higher in trials that met their primary endpoint (53.4% vs. 32.9%, p < .001) and those resulting in FDA approval (63.1% vs. 36.3%, p < .001).
Among treatment interventions, PMW use was most prevalent in systemic therapy trials (50.2%).
The study observed a significant increase in the use of PMWs over time (odds ratio: 1.11/year, p = .001).
The study calls for increased transparency in reporting the funding and use of PMWs.

Academic publishing remains the cornerstone of cancer research and scientific communication of clinical trials. Over the years, there has been increasing interest in the use of professional medical writers (PMWs) to help investigators improve quality of writing and/or reduce the time to publication. Use rates of such PMW services have historically been low, but contemporary data regarding PMW usage remain scarce. With an increasing role of industry sponsorship in cancer clinical trials, we sought to characterize the rate of PMW use among reports of phase III cancer clinical trial results, focusing on factors associated with PMW usage.

Click for Source Download PDF version

PMW usage, phase III oncology trials, professional medical writer assistance

Professional Medical Writer Assistance in Oncology Clinical Trials

Share This Article

Related Topics

Meet Our Innovation Partners

You May Also Like

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN